ClinicalTrials.gg
RecruitingNCT07289646Pegasus 2Updated Oct 15, 2026

Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy

A Phase 3 interventional study of Conventional anatomical planning radiotherapy and Functional Lung avoidance planning in Stereotactic Body Radiotherapy, 68Ga-MAA and Lung Cancer (Diagnosis), sponsored by University Hospital, Brest. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by University Hospital, Brest · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 15, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
418
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 400 studies in Lung Neoplasms with a site in France — 114 open to participants now, 150 under way, 26 of them phase 3. Lung Neoplasms · France.

Planned enrollment
80th of 291
418 · median 170
Started
2026
with 25 others
Phase 3
61 of 400
16 open now
Primary completion
2030-01
later than 126 of 149 live
Registered
378th of 400
by date
Lead sponsor
9 of 400
University Hospital, Brest

Among the 400 studies in Lung Neoplasms with a site in France, this one is the 80th largest by planned enrollment of the 291 interventional ones that give a count, is one of 26 that started in 2026, is one of 61 in phase 3, reaches primary completion later than 126 of the 149 other live ones, and was the 378th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

114 of the 400 studies in Lung Neoplasms with a site in France are open now. Recruiting first, the newest first:

108 more — sign in →

All 114 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 400 studies in Lung Neoplasms with a site in France, or all of them as a file.
02

Study summary

Stereotactic body radiotherapy (SBRT) has an increasing role in the treatment of both primary and secondary lung tumors. However, lung SBRT remains associated with significant radiation induced lung injury (RILI). Indeed, the reported incidence of symptomatic radiation induced lung injury (grade≥2) in the published literature is up to 20%. A current challenge of lung SBRT is therefore to better preserve lung function and to reduce pulmonary toxicity.

During standard lung SBRT planning, dose constraints are defined on the anatomical lung volume. This planning considers the lung as functionally uniform and does not take into account the variability of regional lung function distribution. Functional lung avoidance is an emerging concept in lung radiotherapy (RT). The technique aims at personalizing RT treatment planning to individuals' lung functional distribution, by sparing functional pulmonary areas while prioritizing delivery of high doses to non-functional regions.

68Ga-MAA lung perfusion PET/CT is a novel imaging modality for regional lung function assessment. As compared with conventional lung scintigraphy, lung perfusion PET/CT is inherently a vastly superior technology for image acquisition (higher sensitivity and spatial resolution, greater access to respiratory gated acquisition). A more accurate lung functional mapping improves the possibility of functional lung avoidance planning for SBRT.

The hypothesis is that functional lung avoidance planning guided by 68Ga-MAA perfusion PET/CT, while delivering an optimal dose to the tumor, will reduce the frequency of RILI in patients treated with lung SBRT.

03

Conditions studied

  • Stereotactic Body Radiotherapy
  • 68Ga-MAA
  • Lung Cancer (Diagnosis)

Keywords

  • Stereotactic body radiotherapy
  • 68Ga-MAA lung perfusion
  • PET/CT
  • lung radiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged > 18 years planned to be treated in the radiotherapy department of the participating centers with SBRT for primary or secondary lung tumors will be eligible to participate into the study

Exclusion criteria

Exclusion Criteria:

  • Inability to give
  • Patientsunder guardianship or curatorship
  • Pregnant or breastfeeding women.
  • to the radiolabeled product infused for lung perfusion PET/CT.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
418 participants (estimated)

Study arms

  • Active comparator
    Control group:

    A conventional anatomical planning will be performed.

    Radiation: Conventional anatomical planning radiotherapy

  • Experimental
    Experimental group

    functional planning will be carried out, respecting the standard constraints especially to the tumor and the anatomical lung volume, but also incorporating "lung functional volume" constraints defined by regional lung function mapping.

    Radiation: Functional Lung avoidance planning

Interventions

  • RadiationConventional anatomical planning radiotherapy

    Conventional anatomical planning will be performed

  • RadiationFunctional Lung avoidance planning

    Functional Lung Avoidance guided by lung perfusion PET/CT imaging

06

What researchers measure

Primary outcomes

  1. To determine whether a functional planning guided by lung perfusion PET/CT imaging is superior to a conventional anatomical planning with regards to the occurrence of grade 2 or higher lung toxicity during the year following lung SBRT.

    Occurrence of symptomatic RILI (grade≥2 lung toxicity as assessed using the CTCAE 5.0) during the year following lung SBRT. This evaluation will be performed by a medical oncologist blinded from the allocated arm.

    Time frame: At year after baseline

Secondary outcomes

  1. quality of life assessment

    Quality of life as assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), with scores ranging from 0 to 100; higher scores indicate better quality of life for the global health status and functional scales, and worse symptoms for the symptom scales.

    Time frame: Measured at 3, 6, 9, and 12 months after baseline

  2. quality of life assessment

    Quality of life as assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module (EORTC QLQ-LC29), with scores ranging from 0 to 100; higher scores indicate worse symptom burden.

    Time frame: Measured at 3, 6, 9 and 12 months after baseline

  3. quality of life assessment

    Quality of life as assessed by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire, with index values ranging from -0.594 to 1.0, where higher scores indicate better health-related quality of life.

    Time frame: Measured at 3, 6, 9, and 12 months after baseline

  4. Grade 3 or higher RILI

    Lung toxicity as assessed using the CTCAE 5.0, RTOG and Late effects in normal tissue-subjective objective management analysis (LENT-SOMA) scales

    Time frame: Measured at 3, 6, 9, and 12 months after baseline

  5. Local tumor control;

    Local tumor control;

    Time frame: Measured at 3, 6, 9, and 12 months after baseline

  6. Progression-free survival;

    Progression-free survival

    Time frame: Measured at 3, 6, 9, and 12 months after baseline

  7. Overall survival.

    Overall survival

    Time frame: at 12 months after baseline

Other outcomes

  1. Decrease of lung perfusion

    Lung perfusion PET/CT imaging

    Time frame: at 3 months after baseline

  2. Overall survival

    Grade≥2 lung toxicity during the year following lung SBRT

    Time frame: at 12 months after baseline

07

Study locations

1 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jan 2030, 40 months after the start.

Of 65 non-industry phase 3 interventional studies under Lung Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 99. This study's planned 40 months is below that.

Counting every sponsor, half of 127 studies reached it within 43 months; a quarter within 30 and three quarters within 80.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Jan 2026 → Sep 2026, primary completion Jan 2029 → Jan 2030 and completion May 2029 → Jan 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 17, 2025
StartActual
Sep 4, 2026was Jan 2026
Primary completionEst.
Jan 2030was Jan 2029
CompletionEst.
Jan 2030was May 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
Show 2 sites
  • CHU Brest · Brest, Franceno status→Recruiting
  • Centre de Lutte Contre le Cancer Leon Bérard Lyon · Lyon, Franceno status→Not yet recruiting
Oct 15, 2026
Start date
Jan 15, 2026→Sep 4, 2026 (actual)
Oct 15, 2026
Primary completion
Jan 31, 2029→Jan 2030
Oct 15, 2026
Study completion
May 15, 2029→Jan 2030
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
    Show 2 sites
    • CHU Brest · Brest, Franceno status→Recruiting
    • Centre de Lutte Contre le Cancer Leon Bérard Lyon · Lyon, Franceno status→Not yet recruiting
    Start date Jan 15, 2026→Sep 4, 2026 (now actual)
    Primary completion Jan 31, 2029→Jan 2030
    Study completion May 15, 2029→Jan 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07289646
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Sep 4, 2026
Primary completion
Jan 2030 (estimated)
Completion
Jan 2030 (estimated)
Last update
Oct 15, 2026

Study contacts

Pierre-Yves Le Roux, Professeur
Contact
Pierre-yves.leroux@chu-brest.fr
+33 2 98 22 31 17

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion